Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01703949
Title Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

lymphoma

Therapies

Brentuximab vedotin

Brentuximab vedotin + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.